IOVANCE BIOTHERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
IOVA$8.17+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share information)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| · · Years Ended December 31, | |||||||||
| | 2023 | 2022 | 2021 | ||||||
| | | | | | | | | | |
| Revenue | | $1,189 | | $— | | $— | |||
| Product revenue | | | 1,189 | | | — | | | — |
| Total revenue | | | | | | | | | |
| | | | | ||||||
| Costs and expenses | | | | ||||||
| Cost of sales | | $10,755 | | $— | | $— | |||
| Research and development | | | 344,077 | | | 294,781 | | | 259,039 |
| Selling, general and administrative | | 106,916 | | 104,097 | | 83,664 | |||
| Total costs and expenses | | 461,748 | | 398,878 | | 342,703 | |||
| | | | | ||||||
| Loss from operations | | (460,559) | | (398,878) | | (342,703) | |||
| Other income | | | | ||||||
| Interest income, net | | 13,043 | | 2,985 | | 451 | |||
| Net Loss before income taxes | | $(447,516) | | $(395,893) | | $(342,252) | |||
| Income tax benefit | | | 3,479 | | | — | | | — |
| Net Loss | | $(444,037) | | $(395,893) | | $(342,252) | |||
| Net Loss Per Share of Common Stock, Basic and Diluted | | $(1.89) | | $(2.49) | | $(2.23) | |||
| Weighted Average Shares of Common Stock Outstanding, Basic and Diluted | | 235,131 | | 159,259 | | 153,406 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.